Compounds such as guarana, yerba mate, cocoa, and kola nut may increase biological effects of caffeine in EDs (Zeidn-Chuli et al., 2013)
Being present intracellularly in the reduced form, it boosts different psychological functionalities
falciparum whole cell / Small molecule inhibitor / Infectious diseasesMalariaPhase I GSK3536867GSK3536867 / Salmonella typhoid + paratyphoid A / Bivalent conjugate vaccine / Infectious diseasesSalmonella (typhoid + paratyphoid A)Phase I AGN-151586 / progranulin program (latozinemab)AL001 / Progranulin/sortilin / Monoclonal antibody / Opportunity drivenFrontotemporal dementia with progranulin gene mutationPhase III 26assets ZanubrutinibBTK / Inhibitor / Hematologic Malignancies / Immunology & InflammationTreatment-Naive Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaApprovedRelapsed/Refractory Waldenstrm Macroglobulinemia and Treatment-Nave Waldenstrm MacroglobulinemiaApproved SonrotoclaxBCL2 / Inhibitor / Hematologic MalignanciesTreatment-Naive Chronic Lymphocytic LeukemiaPhase 3Treatment-Naive Chronic Lymphocytic LeukemiaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaApproved TislelizumabPD-1 / Monoclonal Antibody / Lung Cancers / Gastrointestinal Cancers / Other CancersFirst-Line Extensive-Stage Small Cell Lung CancerApprovedFirst-Line Non-Squamous Non-Small Cell Lung CancerApprovedFirst-Line Squamous Non-Small Cell Lung CancerApproved BGB-16673BTK Chimeric Degradation Activation Compound [CDAC] / Hematologic Malignancies / Immunology & InflammationRelapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPhase 3Relapsed/Refractory Mantle Cell LymphomaPhase 2 BlinatumomabCD19 x CD3 / BiTE [Bispecific T-Cell Engager] / Hematologic MalignanciesRelapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (subcutaneous formulation)Phase 2 TarlatamabDLL3 x CD3 / BiTE [Bispecific T-cell Engager] / Lung CancersFirst-Line Extensive-Stage Small Cell Lung CancerPhase 3First-Line Extensive-Stage Small Cell Lung CancerPhase 3Second-Line Small Cell Lung CancerPhase 3 ZanidatamabHER2 Bispecific / Antibody / Gastrointestinal CancersFirst-Line HER2 Positive Gastroesophageal AdenocarcinomaPhase 3Second-Line HER2 Positive Biliary Tract CancerApprovedFirst-Line HER2 positive Biliary Tract CancerPhase 3 BG-68501CDK2 / Inhibitor / Breast/Gynecologic CancersBreast Cancer and Solid TumorsPhase 1 BGB-21447BCL2 / Inhibitor / Breast/Gynecologic CancersHormone Receptor Positive Breast CancerPhase 1 BGB-43395CDK4 / Inhibitor / Breast/Gynecologic CancersBreast Cancer and Solid TumorsPhase 1 BGB-B455Claudin 6 x CD3 Bispecific / Antibody / Breast/Gynecologic CancersGynecologic and Solid TumorsPhase 1 BG-C9074B7-H4 Antibody Drug Conjugate / Breast/Gynecologic CancersBreast Cancer and Solid TumorsPhase 1 BG-75202KAT6A/B / Inhibitor / Breast/Gynecologic CancersBreast CancerPhase 1 BG-75098CDK2 Chimeric Degradation Activation Compound [CDAC] / Breast/Gynecologic CancersBreast CancerPhase 1 BGB-B2033GPC3 x 4-1BB Bispecific / Antibody / Gastrointestinal CancersSolid TumorsPhase 1 BG-C137FGFR2b Antibody Drug Conjugate / Gastrointestinal CancersGastrointestinal CancersPhase 1 BGB-53038Pan-KRAS / Inhibitor / Gastrointestinal CancersLung Cancers and GI CancersPhase 1 BG-C477CEA Antibody Drug Conjugate / Gastrointestinal CancersLung Cancers and GI CancersPhase 1 BG-C0902EGFR x MET x MET Antibody Drug Conjugate / Lung CancersLung Cancers and GI CancersPhase 1 BG-T187EGFR x MET x MET Trispecific / Antibody / Lung CancersLung Cancers and GI CancersPhase 1 BGB-58067MTA Cooperative PRMT5 / Inhibitor / Lung CancersLung Cancers and GI CancersPhase 1 BG-89894MAT2A / Inhibitor / Lung CancersLung Cancers and Solid TumorsPhase 1 BG-60366EGFR Chimeric Degradation Activation Compound [CDAC] / Lung CancersLung CancersPhase 1 BGB-26808HPK1 / Inhibitor / Gastrointestinal CancersSolid Tumors/Pan- TumorPhase 1 XaluritamigSTEAP1 x CD3 Bispecific T-cell Engager (XmAb) / Other CancersMetastatic Castration-Resistant Prostate CancerPhase 1 BGB-45035IRAK4 Chimeric Degradation Activation Compound [CDAC] / Immunology & InflammationRheumatoid ArthritisPhase 2Skin DiseasesPhase 1 24assets NucresiranRNAi therapeutic / Transthyretin Amyloidosis (TTR)ATTR Amyloidosis with CardiomyopathyPhase 3hATTR Amyloidosis with PolyneuropathyPhase 3 ZilebesiranRNAi therapeutic / CardiovascularHypertensionPhase 3REVERSIR HypertensionPhase 1 RapirosiranALN-HSD / HSD / RNAi therapeutic / MetabolicMetabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2 ALN-ANG3ALN-ANG3 / ANG3 / RNAi therapeutic / MetabolicDiabetic Kidney DiseasePhase 2 ALN-4324ALN-4324 / GRB14 / RNAi therapeutic / MetabolicType 2 Diabetes MellitusPhase 1 ALN-2232ALN-2232 / ACVR1C / RNAi therapeutic / MetabolicObesity & Weight ManagementPhase 1 ALN-PNPALN-PNP / PNP / RNAi therapeutic / MetabolicNon-Alcoholic Fatty Liver Disease (NAFLD)Phase 1 ALN-APOC3ALN-APOC3 / APOC3 / RNAi therapeutic / MetabolicDyslipidemiaPhase 1 ALN-CIDEBALN-CIDEB / CIDEB / RNAi therapeutic / MetabolicMetabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 1 Cemdisiran(+/- Pozelimab)RNAi therapeutic / Neuroscience/OtherMyasthenia GravisPhase 3Geographic AtrophyPhase 3 MivelsiranALN-APP / APP / RNAi therapeutic / NeuroscienceCerebral Amyloid Angiopathy (CAA)Phase 2Alzheimers DiseasePhase 1 ALN-HTT02ALN-HTT02 / HTT / RNAi therapeutic / NeuroscienceHuntingtons DiseasePhase 1 ALN-5288ALN-5288 / MAPT / RNAi therapeutic / NeuroscienceAlzheimers DiseasePhase 1 ALN-SODALN-SOD / SOD1 / RNAi therapeutic / NeuroscienceSOD1 Amyotrophic Lateral Sclerosis (ALS)Phase 1 ALN-SNCAALN-SNCA / SNCA / RNAi therapeutic / NeuroscienceParkinsons DiseasePhase 1 Cemdisiran (+Pozelimab)RNAi therapeutic / HematologyParoxysmal Nocturnal HemoglobinuriaPhase 3 ALN-6400ALN-6400 / PLG / RNAi therapeutic / HematologyBleeding DisordersPhase 2 AG-236ALN-TMP / TMP / RNAi therapeutic / HematologyPolycythemia VeraPhase 1 ALN-CFBALN-CFB / CFB / RNAi therapeutic / HematologyParoxysmal Nocturnal HemoglobinuriaPhase 1 Elebsiran (+Tobevibart)RNAi therapeutic / OtherHepatitis D Virus InfectionPhase 2 ALN-BCATALN-BCAT / BCAT / RNAi therapeutic / OtherHepatocellular CarcinomaPhase 1 ALN-4285ALN-4285 / RNAi therapeutic / OtherHealthy VolunteersPhase 1 ALN-4915ALN-4915 / RNAi therapeutic / OtherHealthy VolunteersPhase 1 ALN-F1202ALN-F1202 / RNAi therapeutic / OtherHealthy VolunteersPhase 1 21assets PumitamigPD-L1/VEGF-A / immunomodulator / OncologyMultiple solid tumors
A good medical team will help you manage these proactively, often through gradual dose increases and dietary adjustments
Additionally, the transport and metabolism of pyruvate into the tricarboxylic acid (TCA) cycle are reduced in cases of HF 6,7
Follow all instructions given by the pharmacy to keep the medication safe and effective
